RESUMEN
The identification of somatic driver mutations in cancer has enabled therapeutic advances by identifying drug targets critical to disease causation. However, such genomic discoveries in oncology have not translated into advances for non-cancerous disease since point mutations in a single cell would be unlikely to cause non-malignant disease. An exception to this would occur if the mutation happened early enough in development to be present in a large percentage of a tissue's cellular population. We sought to identify the existence of somatic mutations occurring early in human development by ascertaining base-pair mutations present in one of a pair of monozygotic twins, but absent from the other and assessing evidence for mosaicism. To do so, we genome-wide genotyped 66 apparently healthy monozygotic adult twins at 506 786 high-quality single nucleotide polymorphisms (SNPs) in white blood cells. Discrepant SNPs were verified by Sanger sequencing and a selected subset was tested for mosaicism by targeted high-depth next-generation sequencing (20 000-fold coverage) as a surrogate marker of timing of the mutation. Two de novo somatic mutations were unequivocally confirmed to be present in white blood cells, resulting in a frequency of 1.2×10(-7) mutations per nucleotide. There was little evidence of mosaicism on high-depth next-generation sequencing, suggesting that these mutations occurred early in embryonic development. These findings provide direct evidence that early somatic point mutations do occur and can lead to differences in genomes between otherwise identical twins, suggesting a considerable burden of somatic mutations among the trillions of mitoses that occur over the human lifespan.
Asunto(s)
Mutación Puntual , Gemelos Monocigóticos/genética , Predisposición Genética a la Enfermedad , Estudio de Asociación del Genoma Completo , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Tasa de Mutación , Polimorfismo de Nucleótido Simple , Reproducibilidad de los ResultadosRESUMEN
The search for expression quantitative trait loci has traditionally centred entirely on the process of transcription, whereas variants with effects on messenger RNA translation have not been systematically studied. Here we present a high-throughput approach for measuring translational cis-regulation in the human genome. Using ribosomal association as proxy for translational efficiency of polymorphic messenger RNAs, we test the ratio of polysomal/non-polysomal messenger RNA level as a quantitative trait for association with single nucleotide polymorphisms on the same messenger RNA transcript. We identify one important ribosomal distribution effect, from rs1131017 in the 5'-untranslated region of RPS26, that is in high linkage disequilibrium with the 12q13 locus for susceptibility to type 1 diabetes. The effect on translation is confirmed at the protein level by quantitative western blots, both ex vivo and after in vitro translation. Our results are a proof-of-principle that allelic effects on translation can be detected at a transcriptome-wide scale.
Asunto(s)
Exones/genética , Genoma Humano/genética , Biosíntesis de Proteínas/genética , Línea Celular , Diabetes Mellitus Tipo 1/genética , Predisposición Genética a la Enfermedad , Humanos , Polimorfismo de Nucleótido Simple , Polirribosomas/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Secuencias Reguladoras de Ácidos Nucleicos/genética , Reproducibilidad de los Resultados , Proteínas Ribosómicas/genéticaRESUMEN
ZAC is a transcription factor and cofactor, a strong candidate for transient neonatal diabetes mellitus (TNDM). TNDM involves impaired beta-cell development and is probably due to a double dose of ZAC, which is normally expressed only from the paternal copy. ZAC and Zac1 (its mouse orthologue) are strongly expressed in the proliferating progenitor/stem cells in many systems and also in some differentiated sites in human and mouse, suggesting a dual role in cell proliferation and differentiation control. Little is known about its expression in developing pancreas, the organ affected in TNDM. In this study, we examined ZAC/Zac1 expression in developing mouse and human pancreas by real-time PCR and dual in situ hybridization and immunofluorescence. Overall pancreatic expression drastically declined during gestation and early post-natal life in the mouse, and between the second trimester and adult in the human. Zac1 was predominantly expressed in mesenchyme in the mouse embryo, while ZAC was specifically expressed in islets of the human fetus. Thus, ZAC/Zac1 may play different roles in mouse and human pancreas development. The specific expression of ZAC in the human fetal beta-cells supports it as the gene involved in TNDM and the different expression pattern of Zac1 in mice from human may explain the much milder phenotype in the mouse model of ZAC double dose.
Asunto(s)
Proteínas de Ciclo Celular/metabolismo , Feto/metabolismo , Páncreas/embriología , Factores de Transcripción/metabolismo , Proteínas Supresoras de Tumor/metabolismo , Animales , Proteínas de Ciclo Celular/genética , Expresión Génica , Regulación del Desarrollo de la Expresión Génica , Genes Supresores de Tumor , Humanos , Hibridación in Situ , Células Secretoras de Insulina/metabolismo , Ratones , Ratones Endogámicos C57BL , Especificidad de Órganos , Páncreas/metabolismo , Factores de Transcripción/genética , Proteínas Supresoras de Tumor/genéticaRESUMEN
A doença de Machado-Joseph (MJD) é uma forma de ataxia espinocerebelar (AEC) de herança autossômica dominante, que foi descrita inicialmente em pacientes norte-americanos provenientes das ilhas portuguesas dos Açores. Clinicamente essa doença é caracterizada por uma ataxia cerebelar progressiva, de início tardio e com algumas características associadas tais como: oftalmoplegia, sinais piramidais e extrapiramidais e amiotrofias. A mutaçäo responsável é uma expansäo de trinucleotídeos CAG localizada na regiäo codificadora do gene MJD1. Como parte de um estudo colaborativo sobre AEC no Brasil, nós identificamos 25 famílias, näo aparentadas, segregando a mutaçäo MJD. Nesse artigo nós relatamos as características moleculares do trinucleotídeo CAG presente no gene MJD1 em 62 indivíduos dessas famílias com MJD e em 63 indivíduos que näo apresentam a mutaçäo MJD (126 cromossomos normais) e que foram considerados como controles. Nós observamos uma grande diferença entre os tamanhos dos alelos CAG normais e expandidos. Os alelos normais variaram entre 12 e 33 CAGs (média de 23 CAGs), enquanto que os alelos expandidos tiveram de 66 a 78 CAGs (média de 71.5 CAGs). Näo encontramos nenhuma diferença entre o tamanho dos alelos expandidos em pacientes masculinos e femininos ou entre alelos transmitidos via paterna ou materna. Uma correlaçäo negativa significante foi observada entre a idade de início da doença e o tamanho do segmento de CAG expandido (r=-0,6, P=0,00006); no entanto o tamanho do segmento de CAG expandido foi responsável por somente 40 por cento da variabilidade na idade de início da doença (r2=0.4). Nós observamos também instabilidade do segmento expandido de CAG durante a transmissäo de pais para filhos. Expansöes e contraçöes foram observadas; contudo, houve uma tendência geral para expansäo, com um aumento médio de +2,4 CAGs. Essa tendência para expansäo, pareceu ser maior nas transmissöes paternas (aumento médio de +3,5 CAGs) que nas maternas (aumento médio de +1,3 CAGs). Antecipaçäo foi observada em todas as transmissöes nas quais as idades de início para pais e filhos eram conhecidas, porém, nem todas as antecipaçöes foram acompanhadas de aumento no tamanho do segmento de CAG expandido. Em conclusäo, os nossos resultados mostram que o diagnóstico molecular da mutaçäo responsável pela MJD pode ser estabelecido em todos os indivíduos que apresentam a doença, bem como excluído naqueles portadores de outras formas de AEC.